Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Emis Group Plc LSE:EMIS London Ordinary Share GB00B61D1Y04 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -0.11% 1,868.00 518,034 16:29:30
Bid Price Offer Price High Price Low Price Open Price
1,868.00 1,872.00 1,878.00 1,852.00 1,860.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 168.23 36.09 46.20 40.4 1,183
Last Trade Time Trade Type Trade Size Trade Price Currency
18:01:05 O 1,500 1,868.047 GBX

Emis (EMIS) Latest News (10)

More Emis News
Emis Investors    Emis Takeover Rumours

Emis (EMIS) Discussions and Chat

Emis Forums and Chat

Date Time Title Posts
21/6/202222:50EMIS - Healthcare IT738

Add a New Thread

Emis (EMIS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Emis trades in real-time

Emis (EMIS) Top Chat Posts

DateSubject
26/6/2022
09:20
Emis Daily Update: Emis Group Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker EMIS. The last closing price for Emis was 1,870p.
Emis Group Plc has a 4 week average price of 1,284p and a 12 week average price of 1,242p.
The 1 year high share price is 1,918p while the 1 year low share price is currently 1,116p.
There are currently 63,311,396 shares in issue and the average daily traded volume is 1,253,244 shares. The market capitalisation of Emis Group Plc is £1,182,656,877.28.
21/6/2022
22:09
c3479z: no comment in any quality newspaper over the takeover or even in the Yorkshire Post which is published in Leeds where Emis is based.
21/6/2022
10:12
jdh1602: It had 45% uplift on Friday afternoon, and looked to me like a done deal...almost. I'll keep the last half for a slightly higher price, if it comes soonish. The opportunity cost of frozen cash has to be considered too.
20/6/2022
14:23
wad collector: -- Bidco has agreed that: (a) any Permitted Interim Dividend, being an interim dividend of up to 17.60 pence per EMIS Share and (b) any Permitted Final Dividend, being a final dividend of up to 21.10 pence per EMIS Share, may each be declared and paid to EMIS Shareholders without any reduction in the Consideration. -- If any Permitted Interim Dividend exceeds 17.60 pence and/or any Permitted Final Dividend exceeds 21.10 pence, Bidco reserves the right to reduce the Consideration by an amount equal to such excess amount. -- If the Effective Date occurs prior to 7 October 2022, there will be no Permitted Interim Dividend and no equivalent payment will be made to EMIS Shareholders by Bidco. If no Permitted Final Dividend is declared and paid or becomes payable prior to the Effective Date, no equivalent payment will be made to EMIS Shareholders by Bidco. So if taken over before 7th Oct there will be no dividends. Given that we have been paid the final dividend last month , they have 4 months to avoid an interim divi. Assuming all goes through and no counteroffer. Sp has risen back this morning to about 1875, so I wonder how much point in holding out for another 50p when the market is depressed and buying opportunities elsewhere?
19/6/2022
18:17
grahamburn: But the premium over Friday share price is significant, so IMHO, a counter bid may not materialise.
19/6/2022
00:33
gopher: Re counter offer - rumours in the past that other US software firms interested given EMIS unique position in community care
17/6/2022
20:41
grahamburn: If I'm right - after a quick glance at the RNS - it seems that EMIS will also be able to pay both the interim and final dividend for the current year at a combined rate of up 38.6p per share. That adds considerably to the effective take out price.
22/3/2022
06:53
tole: https://citywire.com/funds-insider/news/expert-view-emis-secure-trust-bank-abcam-workspace-and-dwf/Emis: Just what the doctor orderedHealthcare software group EMIS (EMIS) is delivering consistent cashflow and therefore dividends, and its cash pile means it can continue to increase its payout annually, says Hargreaves Lansdown fund manager Steve Clayton.In preliminary results, the AIM-quoted group reported a 6% increase in revenues to £168m and a 10% rise in earnings per share, all of which allowed it to raise its dividend for the 11th year in a row, by 10% to 35.2p per share.After strong gains on the news last week, the shares closed 2.6% higher at £13.32 on Monday.Clayton, who holds Emis in his HL Select UK Income fund, where it makes up 4% of the £149m portfolio, said the stock 'stands in a position of strength' thanks to 89% of its revenues being recurring and a £64m cash pile.'The consistency of Emis's cashflows feeds through to its dividend paying abilities,' he said.'Eleven years of consecutive increases is a strong track record. With the payment well covered and the business performing, we see plenty of potential for that payout to grow further over time.'He added that the cash buffer 'provides further reassurance to the dividend and also offers the prospect of further boosting growth through funding earnings enhancing acquisitions'.Clayton concluded: 'Overall, these results were just what the doctor ordered and the market seems to agree.'
21/3/2022
10:19
tomps2: EMIS Group (EMIS) full year 2021 results presentation EMIS CEO, Andy Thornburn and CFO, Peter Southbury present the full year 2021 results for the period ended 31 December 2021. Watch the video here: Https://www.piworld.co.uk/company-videos/emis-emis-full-year-2021-results-presentation/ Or listen to the podcast here: Https://piworld.podbean.com/e/emis-group-emis-full-year-2021-results-presentation/
18/3/2022
06:37
tole: EmisThe perceived safety of highly recurring revenue streams has afforded software as a service (SaaS) companies high market ratings. You might think the healthcare software supplier Emis is one of those, with the shares having outperformed the FTSE All-Share more than three times over during the past three years.But while a forward earnings multiple of 21 might look generous, it is not against what has been on offer over the past three years. Roughly 80 per cent of the group's revenue is recurring as its larger health division sells software to the NHS.Hitting a medium-term goal of an adjusted operating margin of 30 per cent could drive its valuation higher. Progress on that score has been impressive: the margin last year came in at 25.9 per cent, up from 22.1 per cent in 2018, when management set out plans to kick-start revenue growth and improve margins.How might it do that? Cost efficiencies are a starting point, which includes refreshing its existing software systems with new technology. But expanding its enterprise division, which focuses on selling medicine dispensation software to pharmacies and hospitals and partnering with smaller third-party technology providers, is the growth engine for the group. The latter, which involves selling software that integrates with the Emis systems to its NHS and private customers, carries little cost for the group and gives a natural kick to margins.Adjusted operating profit for the enterprise division grew a fifth last year, accounting for 40 per cent of the group total, on the back of a 17 per cent revenue rise. That's bang in line with a target to grow the top line at a double-digit rate each year.Growing market share and offering a broader stable of products to customers are the main avenues for revenue growth there. That included acquiring the training system software provider FourteenFish. Analysts at the house broker Numis raised its earnings forecast for this year by 3 per cent off the back of the deal to 58.8p a share, which is also 6 per cent ahead of last year. Emis deserves more credit from the market.ADVICE BuyWHY Sustained growth in margins could prompt a re-rating in the shares
16/2/2022
18:43
km18: ...from last year... Company overview: The group provides healthcare software, information technology and related services in UK, covering 2 segments – Primary&Community Care and Community Pharmacy. The firm’s primary product is EMIS-X – a clinical platform that will enable integrated healthcare ecosystem with the goal to revolutionise the UK’s healthcare system. The benefits it proposes are integrated care across settings, improved interactions with patients and powerful analytics to support the organizations and economies in understanding the population health. Growth strategy is mainly based on a blended approach, with numerous acquisitions over the past decade. As a result, there is some goodwill on the balance sheet but at 27% of total assets supported by £30m of Net income for 2020 should not rise any red flags.  Company has seen a steady growth in revenues over the past 6 years, with increased operational efficiency leading to a much sharper rise in operating profit and net profit (CAGR 26.6% and 46.1% respectively).The company is running low costs to run the business, confirmed by a good EV/EBITDA of 13.1. In addition, there is good visibility for earnings and cash generation coming from long-term contracts. Net cash from the interim report we are discussing today is around £48m. speaking of the interim report, revenue is up by 6.9% to £83m, however, operating profit is slightly down (by negligible 2%) due to increase staff costs and higher amortization charges. As a result, the net income for the period is lower than the 2020.  EMIS has also had to cover a one-off repayment of £7.3m VAT deferred from 2020, reducing the cash flow. Apart from these minor bumps. The performance remains robust. Recurring revenue increased by 4% to $65.8m and is now representing 79% of Group’s revenue....from WealthOracleAM https://wealthoracle.co.uk/detailed-result-full/EMIS/122
Emis share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EMIS
Emis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220626 14:41:51